 | Your browser does not display parts of our website correctly. We use the latest technology available to provide you with a high quality experience; please upgrade your browser to its latest version to view the contents properly: |
PTC Therapeutics, Inc. (PTCT), a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, including rare diseases and oncology.
The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States; commercializes Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and markets Evrysdi for the treatment of SMA in adults and children two months and older in Brazil.
The company's splicing platform includes PTC518, which is being developed for the treatment of Huntington's disease.
PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation to advance drug discovery and development research in regenerative medicine; research collaboration with Massachusetts General Hospital for the treatment of rare genetic disorders resulting from pre-mRNA; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean.
PTC Therapeutics reported a 1st Quarter March 2021 loss of $1.83 per share on revenue of $117.9 million. The consensus estimate was a loss of $1.59 per share on revenue of $95.9 million. Revenue grew 72.8% on a year-over-year basis.
After an earnings miss and a loss of 33.2% since the beginning of the year versus the S&P 500's gain of 11.6%, this stock should continue a downwards path.
We will be trading June 18th put options
Last Trade: $37.99
Trading Range: $37.12 to $70.82
Trade
Profit/Loss Analysis
Closing Summary
|
|
